LifeMD 2025 Q2 Earnings Significant Loss Reduction

LifeMD (LFMD) reported its fiscal 2025 Q2 earnings on August 5, 2025. The company significantly outperformed expectations by reducing its net loss by 77.0% year-over-year and revising its revenue guidance downward due to short-term challenges in its RexMD segment.

Revenue
LifeMD’s total revenue grew 22.8% year-over-year to $62.22 million in 2025 Q2, driven by a strong performance in its telehealth segment. Telehealth revenue accounted for the majority of the company’s income, reaching $48.56 million, while its WorkSimpli segment contributed $13.65 million. Together, these segments formed the foundation of LifeMD’s $62.22 million in total net revenue.

Earnings/Net Income
The company narrowed its net loss to $-1.57 million in Q2 2025, a dramatic 77.0% reduction from the $-6.84 million loss reported in the same period the previous year. On a per-share basis, losses also improved significantly, falling from $0.19 in 2024 Q2 to $0.06 in 2025 Q2, representing a 68.4% improvement. This marked a pivotal turnaround and set a new nine-year high for Q2 net income.

Price Action
LifeMD’s stock price fell 5.73% on the most recent trading day but gained 16.08% over the past full trading week. However, it declined 5.28% month-to-date, reflecting mixed investor sentiment following the earnings report.

Post-Earnings Price Action Review
A strategy of buying LifeMD shares after a positive earnings surprise and holding for 30 days has yielded strong historical returns. Over the past three years, this approach achieved a 250.31% return, outperforming the benchmark by 191.15%. The strategy demonstrated a compound annual growth rate of 54.15% with no recorded maximum drawdown, highlighting its potential for low-risk, high-reward performance.

CEO Commentary
CEO Justin Schreiber highlighted the 30% year-over-year growth in telehealth revenue and 560% increase in adjusted EBITDA, despite challenges in the weight management segment. Schreiber emphasized strategic initiatives, including expansion of GLP-1 and oral therapies, reinvigoration of RexMD through HRT and ED treatments, and the launch of new programs in behavioral health and women’s health. He also noted early signs of recovery in RexMD and expressed confidence in long-term growth potential through underserved markets and AI-driven operational efficiency.

Guidance
LifeMD revised its 2025 consolidated revenue guidance to $250 million–$255 million from $268 million–$275 million, with telehealth revenue now expected to range from $195 million–$200 million, down from $208 million–$213 million. Adjusted EBITDA guidance was also lowered to $27 million–$29 million from $31 million–$33 million, with telehealth adjusted EBITDA now at $14 million–$16 million versus prior $21 million.

Additional News
On August 6, 2025, MarketBeat published its coverage of LifeMD’s Q2 2025 earnings report. The report appeared under the title “LFMD Q2 2025 Earnings Report on 8/4/2025.” However, the content only displayed a loading prompt and required JavaScript and cookie enablement to proceed. No additional financial metrics, such as revenue or earnings figures, were provided, leaving the publication as a placeholder or incomplete report. While the title suggested in-depth analysis, no further actionable information was available within the content at the time of reporting.